Working… Menu
Trial record 47 of 126 for:    "Acute Leukemia" | "Antimetabolites, Antineoplastic"

Fludarabine, Carboplatin, and Topotecan in Treating Patients With Relapsed/Refractory Acute Leukemia or Advanced Myelodysplastic Syndrome

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00005593
Recruitment Status : Completed
First Posted : February 25, 2004
Last Update Posted : June 11, 2010
National Cancer Institute (NCI)
Information provided by:
Case Comprehensive Cancer Center

No Study Results Posted on for this Study
Recruitment Status : Completed
Actual Primary Completion Date : April 2002
Actual Study Completion Date : March 2003
Publications of Results:
Cooper BW, Ksenich P, Koc O, et al.: A phase I and pharmacodynamic study of fludarabine, carboplatin, and topotecan (FCT) for relapsed/refractory acute leukemia (RAL) and advanced myelodysplastic syndromes (MDS). [Abstract] Proceedings of the American Society of Clinical Oncology 20: A-1207, 2001.